Consumer PR team lands great coverage for hepatitis C therapy

---

Thursday August 12, 2010 | No Comments

PC was hired by Pittsburgh’s Three Rivers Pharmaceuticals to build visibility for their hepatitis C retreatment therapy, Infergen.  Infergen received FDA expanded labeling last month and is competing with the news of promising future therapies, all still involved in clinical trials.  Some of our successes to date utilize the “Why Wait?” message, connected to treatment of hepatitis C and mitigating its negative effects on the liver. Increased awareness surrounding this misunderstood,  ”silent killer,” was also an important component of this coverage on Washington’s WUSA. It’s not only an IV Drug User’s illness, just ask Shep…

by PascaleCom

ShareThis